SCHEMBL872500

SCHEMBL872500

CCCCCCCCCCCC(=O)OC(C)CN(C)C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.62
MAPT P10636 3/20 0.54
MAPK1 P28482 3/20 0.54
DNM1 Q05193 1/20 0.51
ALDH1A1 P00352 1/20 0.51
PRKCA P17252 1/20 0.47
PRKCE Q02156 1/20 0.47
PRKCQ Q04759 1/20 0.47
PRKCD Q05655 1/20 0.47
DGKA P23743 1/20 0.47
TSHR P16473 2/20 0.47
CYP1A2 P05177 2/20 0.44
MEN1 O00255 1/20 0.44
GMNN O75496 1/20 0.44
HSP90AA1 P07900 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8396305 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL8394182 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL465982 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL14263115 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL8394932 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL15228719 1.00 LMNA (0.62) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL8394166 0.98 LMNA (0.59) LMNAMAPTMAPK1DNM1ALDH1A1
SCHEMBL992184 0.91 PRKCA (0.54) LMNAMAPTALDH1A1PRKCAPRKCE
SCHEMBL465985 0.91 PRKCA (0.54) LMNAMAPTALDH1A1PRKCAPRKCE
SCHEMBL31374704 0.87 ALDH1A1 (0.58) LMNAMAPTALDH1A1PRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632086-B2 Methods and compositions for treating Raynaud's disease NEXMED HOLDINGS, INC. (US) 2020-04-28 US claimed
US-20180333377-A1 METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE NEXMED HOLDINGS, INC. (US) 2018-11-22 US claimed
EP-2693877-A1 METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE NexMed Holdings, Inc. (US) 2014-02-12 EP claimed
WO-2012139033-A1 METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE NEXMED HOLDINGS, INC. (US) 2012-10-11 WO claimed
EP-1028708-B1 TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E1 DELIVERY NEXMED HOLDINGS INC (US) 2010-01-20 EP claimed
EP-1278495-A4 TOPICAL COMPOSITIONS CONTAINING PROSTAGLANDIN E 1? NEXMED HOLDINGS INC (US) 2006-03-22 EP claimed
WO-2005051960-A2 HYDROCARBYL AMINOHYDROCARBONOATES AND AMINOHYDROCARBONOL HYDROCARBONOATES AS ANTIMICROBIAL AND ANTIVIRAL AGENTS MIDWEST RESEARCH LABORATORIES, LLC (US) 2005-06-09 WO claimed
US-20050113274-A1 Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents MIDWEST RESEARCH LABORATORIES, LLC 2005-05-26 US claimed
EP-1255552-B1 PROSTAGLANDIN COMPOSITIONS FOR THE TREATMENT FOR MALE ERECTILE DYSFUNCTION NEXMED HOLDINGS INC (US) 2005-03-09 EP claimed
EP-0746294-B1 ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS ODONTEX INC (US) 2004-12-22 EP claimed
US-6414028-B1 MIXTURE WITH SKIN PENETRATION INTENSIFIER, POLYSACCHARIDE GUM AND BUFFER NEXMED HOLDINGS, INC. 2002-07-02 US claimed
EP-1178833-A1 TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E 1? DELIVERY Nexmed Holdings, Inc. (US) 2002-02-13 EP claimed
US-6323241-B1 PLACING IN THE FOSSA NAVICULARIS PROSATGLANDIN E1 AND A SKIN PENETRATION ENHANCER OF AMINOALKYLESTERS, GUM, LIPOPHILIC COMPOUND AND ACID BUFFER NEXMED (HOLDINGS) INC. 2001-11-27 US claimed
WO-2001074279-A1 TOPICAL COMPOSITIONS CONTAINING PROSTAGLANDIN E¿1? NEXMED HOLDINGS, INC. (US) 2001-10-11 WO claimed
WO-2001051053-A1 PROSTAGLANDIN COMPOSITIONS AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION NEXMED HOLDINGS, INC. (US) 2001-07-19 WO claimed
WO-2000069469-A1 TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E1 DELIVERY NEXMED HOLDINGS, INC. (US) 2000-11-23 WO claimed
US-6046244-A COMPOSITION COMPRISING PROSTAGLANDIN E1, SKIN PENETRATION ENHANCER, POLYSACCHARIDE GUM, LIPOPHILIC COMPOUND, ACIDIC BUFFER SYSTEM NEXMED HOLDINGS, INC. (US) 2000-04-04 US claimed
EP-0746294-A4 ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS ODONTEX INC (US) 1998-04-22 EP claimed
EP-0746294-A1 ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS ODONTEX, INC. (US) 1996-12-11 EP claimed
WO-1995009590-A1 ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS ODONTEX, INC. (US) 1995-04-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180333377-A1 METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE PTGER1, PTGES, PTGS1 LMNA 1165/4885MAPT 4043/4885MAPK1 3425/4885
US-10632086-B2 Methods and compositions for treating Raynaud's disease PTGER1, PTGES, PTGS1 LMNA 1165/4885MAPT 4043/4885MAPK1 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.